Brief: UK MHRA Withdraws Marketing Authorisation for Ixchiq Chikungunya Vaccine After Safety Review
Tue 10:13
BRIEF-UK MHRA Withdraws Marketing Authorisation for Ixchiq Chikungunya Vaccine After Safety Review Oct 20 (Reuters) - UK's MHRA:
UK'S MHRA: UK MARKETING AUTHORISATION FOR IXCHIQ CHIKUNGUNYA VACCINE WITHDRAWN FOLLOWING SAFETY REVIEW
UK'S MHRA: MHRA HAS CONCLUDED THAT BENEFIT-RISK BALANCE FOR IXCHIQ CHIKUNGUNYA VACCINE IS NO LONGER CONSIDERED FAVOURABLE
Further company coverage: VLS.PA
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Valneva SE
See all newsBrief: UK MHRA Withdraws Marketing Authorisation for Ixchiq Chikungunya Vaccine After Safety Review
Valneva falls as UK regulator revokes Ixchiq vaccine authorisation
Brief: Valneva Provides Update On Ixchiq® In The United Kingdom
Valneva surges after EU regulator validates Lyme disease vaccine application
Brief: Pfizer And Valneva's Lyme Disease Vaccine Candidate Marketing Authorization Application Validated By European Medicines Agency